Vertex Trikafta Approved As First Triple Combo For Cystic Fibrosis With $311,503 Price Tag
Executive Summary
The US FDA cleared the combination in just three months for patients with the most common genetic mutation. Company sets price above double regimen Symdeko, but in line with trailblazer Kalydeco.
You may also be interested in...
Three BRICS Launch Generic Challenge For Vertex’s Landmark CF Therapy
With a suite of vastly expensive and advanced cystic fibrosis therapies entirely under its command, Vertex is facing more heat from patients and advocates in several major low- and middle-income countries.
AbbVie Focuses On Humira’s Formulary Positioning Ahead Of US Biosimilars
A year out from US competition to top-seller Humira, AbbVie is negotiating for formulary position alongside biosimilars. Analysts said success there could delay some patent cliff pain for the originator until 2024.
AbbVie Focuses On Humira’s Formulary Positioning Ahead Of Biosimilars
A year out from the US patent expiration for top-seller Humira, AbbVie is negotiating for formulary position alongside biosimilars. Analysts said success there could delay some patent cliff pain until 2024.